Patterns of emergency room visits, admissions and death following recommended pediatric vaccinations-A population based study of 969,519 vaccination events

Vaccine

Volumn 29, Issue 21, 2011, Pages 3746-3752

  Wilson, Kumanan ^a,b,c   Hawken, Steven ^a   Potter, Beth K ^a,b   Chakraborty, Pranesh ^b,c   Kwong, Jeff ^d,e   Crowcroft, Natasha ^f   Rothwell, Deanna ^a   Manuel, Doug ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^d INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^e PUBLIC HEALTH ONTARIO   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

Author keywords

Health services research; Immunization; Patient safety; Pediatric; Surveillance

Indexed keywords

VACCINE;

ARTICLE; CHILD HOSPITALIZATION; CHILDHOOD MORTALITY; EMERGENCY WARD; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; RISK ASSESSMENT; UNSPECIFIED SIDE EFFECT; VACCINATION;

DRUG TOXICITY; EMERGENCY SERVICE, HOSPITAL; ENDPOINT DETERMINATION; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFLAMMATION; ONTARIO; PATIENT ADMISSION; POPULATION SURVEILLANCE; RISK FACTORS; VACCINATION;

EID: 79955132778     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.044     Document Type: Article

References (24)

1. Fritzell B. Detection of adverse events: what are the current sensitivity limits during clinical development?. Vaccine 2001, 20(Suppl. 1):S47-S48.
2. Centres for Disease Control and Prevention. Possible Side-effects from Vaccines. http://www.cdc.gov/vaccines/vac-gen/side-effects.htm.
3. Immunization safety review: vaccinations and sudden unexpected death in infancy 2003, The National Academies Press, Washington, D.C. K. Stratton, D.A. Almario, T.M. Wizemann, M.C. McCormick (Eds.).
4. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997, 46(RR-7):1-25.
5. Glanz J.M., McClure D.L., Xu S., Hambidge S.J., Lee M., Kolczak M.S., et al. Four different study designs to evaluate vaccine safety were equally validated with contrasting limitations. J Clin Epidemiol 2006, 59(8):808-818.
6. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 1995, 345(8949):567-569.
7. Whitaker H.J., Farrington C.P., Spiessens B., Musonda P. Tutorial in biostatistics: the self-controlled case series method. Stat Med 2006, 25(10):1768-1797.
8. Siegrist C.A. Mechanisms underlying adverse reactions to vaccines. J Comp Pathol 2007, 137Suppl1:S46-50.
9. Mastelic B., Ahmed S., Egan W.M., Del Giudice G., Golding H., Gust I., et al. Mode of action of adjuvants: implications for vaccine safety and design. Biologicals 2010, 38(5):594-601.
10. Aguilar J.C., Rodriguez E.G. Vaccine adjuvants revisited. Vaccine 2007, 25(19):3752-3762.
11. Farrington C.P., Nash J., Miller E. Case series analysis of adverse reactions to vaccines: a comparative evaluation. Am J Epidemiol 1996, 143(11):1165-1173.
12. Farrington C.P., Miller E., Taylor B. MMR and autism: further evidence against a causal association. Vaccine 2001, 19(27):3632-3635.
13. Taylor B., Miller E., Farrington C.P., Petropulos M.C., Favot-Mayaud I., Li J., et al. Autism and measles, mumps, and rubella vaccine: no epidemiological evidence for a causal association. Lancet 1999, 353(9169):2026-2029.
14. Miller E., Andrews N., Grant A., Stowe J., Taylor B. No evidence of an association between MMR vaccine and gait disturbance. Arch Dis Child 2005, 90(3):292-296.
15. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 2004, 351(25):2611-2618.
16. Juurlink D.N., Stukel T.A., Kwong J., Kopp A., McGeer A., Upshur R.E., et al. Guillain-Barre syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med 2006, 166(20):2217-2221.
17. Decker M.D., Edwards K.M., Steinhoff M.C., Rennels M.B., Pichichero M.E., Englund J.A., et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995, 96(3 Pt 2):557-566.
18. Gustafsson L., Hallander H.O., Olin P., Reizenstein E., Storsaeter J. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N Engl J Med 1996, 334(6):349-355.
19. Virtanen M., Peltola H., Paunio M., Heinonen O.P. Day-to-day reactogenicity and the healthy vaccinee effect of measles-mumps-rubella vaccination. Pediatrics 2000, 106(5):E62.
20. Fine P.E., Chen R.T. Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 1992, 136(2):121-135.
21. Davis R.L., Marcuse E., Black S., Shinefield H., Givens B., Schwalbe J., et al. MMR2 immunization at 4 to 5 years and 10 to 12 years of age: a comparison of adverse clinical events after immunization in the Vaccine Safety Datalink Project. The Vaccine Safety Datalink Team. Pediatrics 1997, 100(5):767-771.
22. Chen R.T., DeStefano F., Davis R.L., Jackson L.A., Thompson R.S., Mullooly JP, et al. The Vaccine Safety Datalink: immunization research in health maintenance organizations in the USA. Bull World Health Organ 2000, 78(2):186-194.
23. Chen R.T., Glasser J.W., Rhodes P.H., Davis R.L., Barlow W.E., Thompson R.S., et al. Vaccine Safety Datalink Project: a new tool for improving vaccine safety monitoring in the United States. The Vaccine Safety Datalink Team. Pediatrics 1997, 99(6):765-773.
24. Scheifele D.W., Halperin S.A. Immunization Monitoring Program, Active: a model of active surveillance of vaccine safety. Semin Pediatr Infect Dis 2003, 14(3):213-219.